Mesoblast Limited (MEOBF)
- GlobeNewswire
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40 million available from existing facilities subject to certain milestonesNet operating spend of US$65.8 million for the 12 months ended June 2022, a 35% reduction on comparative year, with continued focus on cost controlBLA resubmission for remestemcel-L in children with SR-aGVHD expected to be filed this
- GlobeNewswire
Mesoblast Corporate Update and Financial Results Webcast
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June 30, 2022. The webcast will begin at 6.30pm EDT, Tuesday, August 30; 8.30am AEST, Wednesday, August 31, 2022. It can be accessed via: https://webcast.openbriefing.com/8875/ The archived webcast will be available on th
- GlobeNewswire
Jane Bell Joins Mesoblast Board
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking and finance lawyer with 22 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Australia and the United Kingdom, including funds management, mergers, acquisitions, and divestment
